The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing

Thrombosis Research

Volumn 126, Issue 5, 2010, Pages 442-446

  Verkleij, Chantal J N ^a   Roelofs, Joris J T H ^a   Havik, Stefan R ^a   Meijers, Joost C M ^a   Marx, Pauline F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Diabetes mellitus; Fibrinolysis; Hyperglycaemia; TAFI; Wound healing

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FIBRINOLYSIS; GENE EXPRESSION; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STREPTOZOCIN DIABETES; WOUND CLOSURE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANIMALS; CARBOXYPEPTIDASE U; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; HYPERGLYCEMIA; MICE; MICE, INBRED C57BL; WOUND HEALING;

EID: 78149283443     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.08.008     Document Type: Article

References (22)

1. R.E. Pecoraro, G.E. Reiber, and E.M. Burgess Pathways to diabetic limb amputation. Basis for prevention Diabetes Care 13 1990 513 521
2. M. Kurkinen, A. Vaheri, P.J. Roberts, and S. Stenman Sequential appearance of fibronectin and collagen in experimental granulation tissue Lab Invest 43 1980 47 51
3. G. Broughton, J.E. Janis, and C.E. Attinger Wound healing: an overview Plast Reconstr Surg 117 2006 1e 32e
4. M.B. Witte, and A. Barbul General principles of wound healing Surg Clin North Am 77 1997 509 528
5. H. Smola, G. Thiekotter, and N.E. Fusenig Mutual induction of growth factor gene expression by epidermal-dermal cell interaction J Cell Biol 122 1993 417 429
6. Y.P. Xia, Y. Zhao, J. Marcus, P.A. Jimenez, S.M. Ruben, and P.A. Moore Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischaemia-impaired rabbit ear model and on scar formation J Pathol 188 1999 431 438
7. M.C. Regan, S.J. Kirk, H.L. Wasserkrug, and A. Barbul The wound environment as a regulator of fibroblast phenotype J Surg Res 50 1991 442 448
8. H.P. Ehrlich, and T.M. Krummel Regulation of wound healing from a connective tissue perspective Wound Repair Regen 4 1996 203 210
9. J.C. Chan, D.A. Duszczyszyn, F.J. Castellino, and V.A. Ploplis Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice Am J Pathol 159 2001 1681 1688
10. J. Romer, T.H. Bugge, C. Pyke, L.R. Lund, M.J. Flick, and J.L. Degen Impaired wound healing in mice with a disrupted plasminogen gene Nat Med 2 1996 287 292
11. C.M. Swaisgood, E.L. French, C. Noga, R.H. Simon, and V.A. Ploplis The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system Am J Pathol 157 2000 177 187
12. E.A. Te Velde, G.T. Wagenaar, A. Reijerkerk, M. Roose-Girma, I.H. Borel Rinkes, and E.E. Voest Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor J Thromb Haemost 1 2003 2087 2096
13. I. Juhan-Vague, C. Roul, M.C. Alessi, J.P. Ardissone, M. Heim, and P. Vague Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin Thromb Haemost 61 1989 370 373
14. Y. Hori, E.C. Gabazza, Y. Yano, A. Katsuki, T. Suzuki, and Y. Adachi insulin resistance is associated with iincreased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients J Clin Endocrinol Metabolism 87 2002 660 665
15. N. Kitagawa, Y. Yano, E.C. Gabazza, N.E. Bruno, R. Araki, and K. Matsumoto Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients Diabetes Res Clin Pract 73 2006 150 157
16. Y. Yano, N. Kitagawa, E.C. Gabazza, K. Morioka, H. Urakawa, and T. Tanaka Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normatensive type 2 diabetic patients with microalbuminuria J Clin Endocrinol Metabolism 88 2003 736 741
17. P.F. Marx, C.J. Verkleij, M.V. Seron, and J.C. Meijers Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research Mini Rev Med Chem 9 2009 1165 1173
18. T. Szkudelski The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas Physiol Res 50 2001 537 546
19. J. Willemse, J. Leurs, R. Verkerk, and D. Hendriks Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate Anal Biochem 340 2005 106 112
20. R. Renckens, J.J. Roelofs, S.A. ter Horst, C. van 't Veer, S.R. Havik, and S. Florquin Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice J Immunol 175 2005 6764 6771
21. A. Harmanci, N. Kandemir, S. Dagdelen, N. Gonc, Y. Buyukasik, and A. Alikasifoglu Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state J Diabetes Complications 20 2006 40 44
22. J.P. Antovic, M. Yngen, C.G. Ostenson, A. Antovic, H.N. Wallen, and G. Jorneskog Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications Blood Coagul Fibrinolysis 14 2003 551 556